WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.